Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PTGIR | P43119 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipazilide SCHEMBL9877353 | 0.99 | MAPK1 (0.54) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL10358746 | 0.96 | TP53 (0.52) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL9877376 | 0.95 | MAPK1 (0.51) | MAPK1KMT2AMEN1TP53GAA | |
| Ipazilide SCHEMBL120491 | 0.95 | MAPK1 (0.51) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL9878032 | 0.95 | MAPK1 (0.51) | MAPK1KMT2AMEN1TP53GAA | |
| Ipazilide SCHEMBL120490 | 0.95 | MAPK1 (0.51) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL9877916 | 0.94 | MAPK1 (0.50) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL9878705 | 0.94 | POLB (0.51) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL10556849 | 0.94 | MAPK1 (0.50) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL9876977 | 0.93 | MEN1 (0.52) | MAPK1KMT2AMEN1TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007009462-A2 | TREATMENT OF MIGRAINE AND HEADACHES | REGION HOVEDSTADEN V/GLOSTRUP HOSPITAL (DK) | 2007-01-25 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-4870095-A | 1H-pyrazole-1-alkanamides, antiarrhythmic compositions and use | STERLING DRUG, INC. (US) | 1989-09-26 | — | — | US | claimed |
| EP-0299407-A1 | 1H-pyrazole-1-alkanamides and preparation useful as antiarrhythmic agents | STERLING DRUG INC. (US) | 1989-01-18 | — | — | EP | claimed |
| JP-1063573-A | — | — | None | — | — | JP | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-4916150-A | 1H-pyrazole-1-alkanamines antiarrhythmic compositions and use | STERLING DRUG INC. (US) | 1990-04-10 | — | — | US | disclosed |
| US-4870095-A | 1H-pyrazole-1-alkanamides, antiarrhythmic compositions and use | STERLING DRUG, INC. (US) | 1989-09-26 | — | — | US | disclosed |
| EP-0299407-A1 | 1H-pyrazole-1-alkanamides and preparation useful as antiarrhythmic agents | STERLING DRUG INC. (US) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | MAPK1 3836/4885KMT2A 1839/4885MEN1 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.